-
Understanding Antibody Staining for Antigen Detection in Flow Cytometry(Post)
Flow cytometry stands as a pivotal technique in the realms of molecular biology and immunology, enabling the analysis of physical and chemical characteristics of cells or particles as they flow in
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements(Post)Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
CD31: A Comprehensive Look at an Essential Biomarker(Post)What is CD31? CD31, also known as PECAM-1, was originally described as a cell surface antigen present on platelets and megakaryocytes. CD31 is
The PD-1 Pathway and Cancer Immunotherapy(Post)The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.
CXCL16 – Review(Post)CXCL16 CXCL16, a unique member of the CXC chemokine family, stands at the crossroads of immune modulation and vascular biology. Initially discovered as a chem
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Tidutamab: Unlocking the Potential of SSTR2-Targeting in Oncology Research(Post)Quick Facts About TidutamabWhat is Tidutamab?Tidutamab is a monoclonal antibody designed to target somatostatin receptor 2 (SSTR2), a key protein involved in various neuroendocrine tumor
The Essential Guide to DNA: Components, Purpose and Purification Methods(Post)Exploring DNA's essence, this guide illuminates its structure, function, and purification techniques, essential in fields like medicine and biotechnology. Key Takeaways: DNA's Struct
Exploring Organelle Markers: Illuminating the Cellular Landscape(Post)The eukaryotic cell is a complex and dynamic system with distinct membrane-bound compartments known as organelles, each performing specialized functions essential for cellular survival. To better
MAPK Signaling: Unraveling the Pathway of Mitogen Stimulation(Post)Cell Signalling · Kinase CascadesMAPK Signaling: The Pathway of Mitogen StimulationThe mitogen-activated protein kinase (MAPK) pathway is one of the most important signalling cascades in biology, conv
Platelets and Immunothrombosis (Page) Icrucumab: Exploring the Role of Anti-Angiogenic Therapy in Cancer Research(Post)Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe
NLRP3 Inflammasome and Pyroptosis: Pathway, Function and Assays(Post)The inflammasome is one of the few innate pathways that destroys the cell it activates. A macrophage that assembles NLRP3 has committed to a decision it cannot reverse: a priming signal through TLR4
The EGFR/HER Family: Dimerisation, Ligand Independence & Resistance(Page) Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
Imalumab: Unveiling Its Mechanism, Clinical Potential, and Biosimilar Advancements(Post)What You Need to Know About ImalumabWhat is Imalumab?Imalumab is a monoclonal antibody targeting macrophage migration inhibitory factor (MIF), a key regulator of inflammation and immune